BRPI0506736B8 - - Google Patents

Info

Publication number
BRPI0506736B8
BRPI0506736B8 BRPI0506736A BRPI0506736B8 BR PI0506736 B8 BRPI0506736 B8 BR PI0506736B8 BR PI0506736 A BRPI0506736 A BR PI0506736A BR PI0506736 B8 BRPI0506736 B8 BR PI0506736B8
Authority
BR
Brazil
Prior art keywords
subject invention
compounds
gastroparesis
variables
safe
Prior art date
Application number
Other languages
English (en)
Portuguese (pt)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BRPI0506736A publication Critical patent/BRPI0506736A/pt
Publication of BRPI0506736B1 publication Critical patent/BRPI0506736B1/pt
Publication of BRPI0506736B8 publication Critical patent/BRPI0506736B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Fats And Perfumes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0506736-7A 2004-01-07 2005-01-07 Compostos estereoisoéricos para o tratamento de distúrbios gastrointestinais e no sistema nervoso central, e composições BRPI0506736B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US53489204P 2004-01-07 2004-01-07
US60/534,892 2004-01-07
US56093804P 2004-04-09 2004-04-09
US60/560,938 2004-04-09
PCT/US2005/000510 WO2005068461A1 (en) 2004-01-07 2005-01-07 Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders

Publications (3)

Publication Number Publication Date
BRPI0506736A BRPI0506736A (pt) 2007-05-15
BRPI0506736B1 BRPI0506736B1 (pt) 2018-08-21
BRPI0506736B8 true BRPI0506736B8 (enExample) 2021-05-25

Family

ID=34798839

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0506736-7A BRPI0506736B1 (pt) 2004-01-07 2005-01-07 Compostos estereoisoéricos para o tratamento de distúrbios gastrointestinais e no sistema nervoso central, e composições

Country Status (19)

Country Link
US (2) US7176218B2 (enExample)
EP (2) EP1704146B1 (enExample)
JP (2) JP5200288B2 (enExample)
KR (1) KR101240464B1 (enExample)
CN (1) CN101824033B (enExample)
AT (1) ATE464308T1 (enExample)
AU (2) AU2005205531B2 (enExample)
BR (1) BRPI0506736B1 (enExample)
CA (1) CA2551686C (enExample)
CY (1) CY1110901T1 (enExample)
DE (1) DE602005020580D1 (enExample)
DK (2) DK1704146T3 (enExample)
ES (2) ES2415830T3 (enExample)
IL (1) IL176569A (enExample)
MX (1) MXPA06007853A (enExample)
NO (1) NO337741B1 (enExample)
PT (2) PT2194053E (enExample)
RU (1) RU2374244C2 (enExample)
WO (1) WO2005068461A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211230D0 (en) 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
PT2194053E (pt) * 2004-01-07 2013-07-08 Armetheon Inc Derivados de metoxipiperidina para utilização no tratamento de distúrbios gastrointestinais e do sistema nervoso central
US8524736B2 (en) 2004-01-07 2013-09-03 Armetheon, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US8138204B2 (en) * 2004-01-07 2012-03-20 Aryx Therapeutics, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
MY150958A (en) 2005-06-16 2014-03-31 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
CN101258151B (zh) * 2005-08-31 2012-10-10 ARYx医疗有限公司 用于治疗胃肠系统和中枢神经系统疾病的立体异构化合物的合成方法及中间体
BRPI0615691A8 (pt) * 2005-08-31 2017-08-15 Aryx Therapeutics Inc Método para a preparação de 6-((3s,4r)-4-(4-amino-5-cloro-2-metoxibenzamido)-3-metoxipiperidin-1-il) hexanoato de (r)-quinuclidin-3-ila ou sal do mesmo
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
CA2631991A1 (en) * 2005-12-23 2007-06-28 Astrazeneca Ab Heterocyclic gaba-b modulators
WO2007149929A1 (en) * 2006-06-23 2007-12-27 Aryx Therapeutics, Inc. Piperidine derivatives for the treatment of gastrointestinal and cns disorders
CN101402633A (zh) 2007-09-11 2009-04-08 上海恒瑞医药有限公司 苯甲酰胺类衍生物、其制备方法及其在医药上的用途
WO2010062959A1 (en) * 2008-11-26 2010-06-03 Aryx Therapeutics, Inc. 5-ht4 receptor agonists for treating irritable bowel syndrome and colonic hypersensitivity
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
US20120295942A1 (en) 2010-02-01 2012-11-22 Nicholas James Devereux Pyrazolo[5,1b]oxazole Derivatives as CRF-1 Receptor Antagonists
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
CN102753527B (zh) 2010-02-02 2014-12-24 诺华股份有限公司 用作crf受体拮抗剂的环己基酰胺衍生物
US8546416B2 (en) 2011-05-27 2013-10-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
PL395470A1 (pl) * 2011-06-29 2013-01-07 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Sulfonamidowe pochodne amin alicyklicznych do leczenia chorób osrodkowego ukladu nerwowego
KR20150003771A (ko) 2012-05-03 2015-01-09 노파르티스 아게 그렐린 수용체 효능제로서의 2,7-디아자-스피로[4.5]데스-7-일 유도체의 l-말레이트 염 및 그의 결정질 형태
CN114344300A (zh) * 2014-05-16 2022-04-15 拉夸里亚创药株式会社 胃轻瘫用5-ht4受体激动剂
US20220062621A1 (en) 2015-02-24 2022-03-03 Elira, Inc. Electrical Stimulation-Based Weight Management System
US9956393B2 (en) 2015-02-24 2018-05-01 Elira, Inc. Systems for increasing a delay in the gastric emptying time for a patient using a transcutaneous electro-dermal patch
US10765863B2 (en) 2015-02-24 2020-09-08 Elira, Inc. Systems and methods for using a transcutaneous electrical stimulation device to deliver titrated therapy
US10376145B2 (en) 2015-02-24 2019-08-13 Elira, Inc. Systems and methods for enabling a patient to achieve a weight loss objective using an electrical dermal patch
CN115227969A (zh) 2015-02-24 2022-10-25 伊莱拉股份有限公司 使用电极皮肤贴实现食欲调节或改善饮食依从性的方法
US10335302B2 (en) 2015-02-24 2019-07-02 Elira, Inc. Systems and methods for using transcutaneous electrical stimulation to enable dietary interventions
US10864367B2 (en) 2015-02-24 2020-12-15 Elira, Inc. Methods for using an electrical dermal patch in a manner that reduces adverse patient reactions
US11495028B2 (en) * 2018-09-28 2022-11-08 Intel Corporation Obstacle analyzer, vehicle control system, and methods thereof
WO2020096911A1 (en) 2018-11-05 2020-05-14 Renexxion, Llc Methods of producing naronapride trihydrate
US10570127B1 (en) * 2018-11-05 2020-02-25 Renexxion, Llc Material and methods for the treatment of gastro-intestinal disorders

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
GB1425706A (en) 1972-06-30 1976-02-18 Wyeth John & Brother Ltd Piperidine derivatives
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4962115A (en) * 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
CA1183847A (en) 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5057525A (en) * 1981-10-01 1991-10-15 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives
US5137896A (en) * 1981-10-01 1992-08-11 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)benzamide derivatives
GB8519707D0 (en) * 1985-08-06 1985-09-11 Fordonal Sa Chemical compounds
US4870074A (en) * 1986-04-30 1989-09-26 Dainippon Pharmaceutical Co., Ltd. Substituted benzamide derivatives, for enhancing gastrointestinal motility
NZ225152A (en) * 1987-07-17 1990-04-26 Janssen Pharmaceutica Nv Heterocyclically substituted piperidinyl benzamides as pharmaceuticals
CA1317940C (en) * 1987-09-25 1993-05-18 Georges H. P. Van Daele Substituted n-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides
US5041454A (en) * 1987-09-25 1991-08-20 Janssen Pharmaceutica N.V. Novel substituted N-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides
US4975439A (en) * 1987-09-25 1990-12-04 Janssen Pharmaceutical N.V. Novel substituted N-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides
JP3104142B2 (ja) * 1991-02-15 2000-10-30 北陸製薬株式会社 ベンズアミド誘導体
US5395832A (en) * 1991-02-15 1995-03-07 Hokuriku Seiyaku Co., Ltd. Benzamide derivatives
TW243449B (enExample) * 1991-02-15 1995-03-21 Hokuriku Pharmaceutical
IT1260485B (it) * 1992-05-29 1996-04-09 Procedimento e dispositivo per il trattamento dell'obesita' di un paziente
JPH08502032A (ja) * 1992-07-07 1996-03-05 セプラコア インコーポレーテッド 胃食道逆流疾患およびその他の障害を治療するために▲（−）▼シサプリドを使用する方法
EP0651639A4 (en) * 1992-07-07 1996-06-26 Sepracor Inc METHODS OF USING CISAPRIDE (+) FOR THE TREATMENT OF GASTROSOPHAGIC REFLUX AND OTHER DISORDERS.
CA2148700A1 (en) 1992-11-05 1994-05-11 Laramie Mary Gaster Piperidine derivatives as 5-ht4 receptor antagonists
US5472866A (en) * 1992-12-24 1995-12-05 Synaptic Pharmaceutical Corporation DNA encoding 5-HT4A serotonin receptors
US5705798A (en) * 1994-12-16 1998-01-06 Mastercard International Inc. System and method for processing a customized financial transaction card
US5712293A (en) * 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
US6147093A (en) * 1996-07-19 2000-11-14 Sepracor Inc. Methods for treating gastroesophageal reflux disease
CN1196681C (zh) 1997-07-11 2005-04-13 詹森药业有限公司 (+)诺西沙必利用于制备5－ht3和5ht4 介导的疾病的药物中的用途
JPH11292846A (ja) 1998-02-10 1999-10-26 Hokuriku Seiyaku Co Ltd ベンズアミド誘導体及びそれを含有する医薬
AR022338A1 (es) 1999-02-04 2002-09-04 Hokuriku Pharmaceutical Un compuesto de benzamida, medicamento que lo contiene, y uso para la manufactura de un medicamento para el tratamiento o prevencion de una enfermedad digestiva o para mejorar la movilidad del tracto gastrointestinal.
DE19933926A1 (de) 1999-07-20 2001-01-25 Boehringer Ingelheim Pharma Biphenylderivate, ihre Herstellung und ihre Verwendung als Arzneimittel
US20040092511A1 (en) * 1999-12-10 2004-05-13 Billstein Stephan Anthony Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders
EP1292314A2 (en) 2000-05-23 2003-03-19 The Trustees of Columbia University in the City of New York Method for treating respiratory disorders associated with pulmonary elastic fiber injury comprising the use of glycosaminoglycans
US6552046B2 (en) * 2000-06-07 2003-04-22 Aryx Therapeutics Materials and methods for the treatment of gastroesophageal reflux disease
MXPA03000145A (es) * 2002-01-07 2003-07-15 Pfizer Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4.
PT2194053E (pt) * 2004-01-07 2013-07-08 Armetheon Inc Derivados de metoxipiperidina para utilização no tratamento de distúrbios gastrointestinais e do sistema nervoso central

Also Published As

Publication number Publication date
KR101240464B1 (ko) 2013-03-08
IL176569A0 (en) 2006-10-31
ES2415830T3 (es) 2013-07-29
EP1704146B1 (en) 2010-04-14
WO2005068461A1 (en) 2005-07-28
RU2006128589A (ru) 2008-02-20
RU2374244C2 (ru) 2009-11-27
CN101824033B (zh) 2013-02-27
AU2005205531B2 (en) 2011-03-17
NO20063568L (no) 2006-08-07
ES2344568T3 (es) 2010-08-31
CY1110901T1 (el) 2015-06-10
JP2012102102A (ja) 2012-05-31
EP2194053B1 (en) 2013-03-27
PT1704146E (pt) 2010-06-30
MXPA06007853A (es) 2007-01-26
NO337741B1 (no) 2016-06-13
CN101824033A (zh) 2010-09-08
US20050197363A1 (en) 2005-09-08
JP5524939B2 (ja) 2014-06-18
US7282509B2 (en) 2007-10-16
AU2008243243A1 (en) 2008-12-04
US20050176757A1 (en) 2005-08-11
JP2007517891A (ja) 2007-07-05
CA2551686A1 (en) 2005-07-28
EP2194053A1 (en) 2010-06-09
BRPI0506736A (pt) 2007-05-15
DK1704146T3 (da) 2010-06-28
IL176569A (en) 2011-06-30
KR20060128966A (ko) 2006-12-14
BRPI0506736B1 (pt) 2018-08-21
US7176218B2 (en) 2007-02-13
DE602005020580D1 (de) 2010-05-27
JP5200288B2 (ja) 2013-06-05
CA2551686C (en) 2014-09-23
AU2008243243B2 (en) 2011-03-10
PT2194053E (pt) 2013-07-08
EP1704146A1 (en) 2006-09-27
ATE464308T1 (de) 2010-04-15
AU2005205531A1 (en) 2005-07-28
DK2194053T3 (da) 2013-07-01

Similar Documents

Publication Publication Date Title
BRPI0506736B8 (enExample)
NO20081562L (no) Syntetiske metoder og mellomprodukt for stereoisomeriske forbindelser som er nyttige for behandlingen av gastrointestinale og sentralnervesystemersykdommer
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
TW200613280A (en) Heteroaroyl-substituted serineamides
TW200716558A (en) Heteroaroyl-substituted serineamides
GB0325956D0 (en) Novel compounds
IL248993A0 (en) erbb inhibitors
UA92355C2 (en) urn:schemas-microsoft-com:office:smarttags2,4-DIAMINO-PYRIMIDINES USED AS AURORAINHIBITORS
GEP20084420B (en) Use of imidazole compounds for the treatment of neurodegenerative disorders
TW200734311A (en) New compounds
PL1874282T3 (pl) Sposoby i kompozycje do leczenia zaburzeń OUN
IL196391A0 (en) Pyrrolopyrimidines for pharmaceutical compositions
TW200612892A (en) Novel compounds
TW200531689A (en) Therapeutic agents
ATE450514T1 (de) Piperazinylalkylpyrazol-derivate zur verwendung als selektive calciumkanalblocker des t-typs und verfahren zu ihrer herstellung
TW200503710A (en) Novel compounds
TNSN07165A1 (en) Organic compounds
WO2006040181A3 (en) 4-phenylsulfonamidopiperidines as calcium channel blockers
TW200726767A (en) Chemical compounds 2
NO20072060L (no) 2-acylaminotiazolderivater
WO2002096420A3 (en) Method for treating nerve injury caused by surgery
PT1606288E (pt) Derivados de benzenossulfonamida, processo para a sua preparação e a sua utilização para tratamento da dor
MX2007016373A (es) Compuestos de piridil y piridonil estereoisomericos y metodos para el tratamiento de trastornos gastrointestinales y del sistema nervioso central.
WO2005095348A3 (en) Pyrazole-amine compounds for the treatment of neurodegenerative disorders
ATE520408T1 (de) Zubereitung zur behandlung von mineralstoffmangel

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25C Requirement related to requested transfer of rights

Owner name: ARYX THERAPEUTICS (US)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B25A Requested transfer of rights approved

Owner name: ARYX THERAPEUTICS, INC. (US)

B25A Requested transfer of rights approved

Owner name: ARMETHEON, INC. (US)

B25A Requested transfer of rights approved

Owner name: NARONAPRIDE LLC (US)

B25D Requested change of name of applicant approved

Owner name: RENEXXION LLC (US)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/01/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF